



STALLERGENES ENTERS THE NETHERLANDS THROUGH A JOINT VENTURE AGREEMENT

Antony, France (Feb. 13, 2007) – Stallergenes SA today announced that it has set up a joint-venture in the Netherlands in partnership with the Dutch company Sanmed B.V.

The agreement represents an important step forward in Stallergenes' strategy to be present in the Dutch market, the fifth largest desensitization market in Europe. In 2006, the Dutch market has reached an estimated value of 37 million euros and is dominated by sublingual treatments, which have experienced a growth of 18%.

Under the terms of the agreement, 51% of the shares of the newly established entity Stallergenes B.V will belong to Stallergenes S.A. The objective of Stallergenes B.V is to distribute and promote the existing range of Stallergenes' products on the Dutch market, and then launch the sublingual desensitization tablets once approved through the Mutual Recognition Procedure.

"We are very pleased to enter this agreement with Sanmed B.V.. The Company has a demonstrated track record in launching and promoting licensed-in products on the Dutch market" said Albert Saporta, Chairman and CEO of Stallergenes. "We are confident that their market knowledge and their local infrastructure, combined with our long-standing expertise in desensitization should help develop the very dynamic Dutch market."

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

Pioneer and leader in sublingual desensitization treatments, Stallergenes devotes more than 15% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

With headquarters in France, Stallergenes markets its products in approximately 40 countries. In 2006, Stallergenes reached a turnover of 126.5 million euros, half of which are achieved internationally.

Stallergenes is listed on the Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN Code:FR0000065674

Reuters Code:GEN.PA

Bloomberg Code: GEN.FP

Additional information is available on www.stallergenes.com.

About Sanmed B.V

With headquarters in The Netherlands, Sanmed B.V. is a sister company of Lapis Lazuli International N.V., specializing in eyecare.

Sanmed B.V. is specialized in the development, production and marketing of evidence-based nutraceuticals (support visual function; modulation psycho-neuroimmunological system in relation to degenerative health conditions) and related medical devices.

For more information please contact:

Press relations: Lise Lemonnier Communication Manager Stallergenes S.A. Tel: 331 55 59 23 10 Fax: 331 55 59 21 29 Email: llemonnier@stallergenes.fr	Investor and analyst relations: Christian Thiry Chief Financial Officer Tel: 331 55 59 20 95 Email: investorrelations@stallergenes.fr Lucile de Fraguier Pavie Finance Tel: 331 42 15 04 39 Email: contact@pavie-finance.com
--	---